Trials / Unknown
UnknownNCT06212245
A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
An Open-label Single-arm Clinical Study to Assess the Efficacy and Safety of Inebilizumab in Chinese Adult Patients With Neuromyelitis Optica Spectrum Disorders (NMOSD)
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 33 (estimated)
- Sponsor
- Hansoh BioMedical R&D Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy and safety of Inebilizumab in Chinese adult patients with neuromyelitis optica spectrum disorders.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inebilizumab | Participants will receive IV inebilizumab 300 mg |
Timeline
- Start date
- 2024-02-25
- Primary completion
- 2024-12-25
- Completion
- 2025-06-25
- First posted
- 2024-01-18
- Last updated
- 2024-01-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06212245. Inclusion in this directory is not an endorsement.